Source-linked trial list

The registrations behind this number.

Verify the exact trial registrations behind a company, intervention, programme or topic count.

Exact trial list

16 matching trial registrations

Intervention brolucizumab
Topic Vision ageing

Showing 1–16 of 16. Every record below meets all the filters shown above.

CompletedNCT04543331

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Phase not reported · 572 planned enrolment

Countries listed: 1
Registry update: July 29, 2026

Verify in the registry →

Active Not RecruitingNCT04932980

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

Phase not reported · 80 planned enrolment

Countries listed: 1
Registry update: December 8, 2025

Verify in the registry →

CompletedNCT04679935

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

PHASE4 · 52 planned enrolment

Countries listed: 2
Registry update: September 26, 2025

Verify in the registry →

CompletedNCT04774926

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

PHASE4 · 122 planned enrolment

Countries listed: 1
Registry update: May 16, 2025

Verify in the registry →

TerminatedNCT04764656

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Phase not reported · 81 planned enrolment

Countries listed: 1
Registry update: March 25, 2025

Verify in the registry →

RecruitingNCT04985487

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Phase not reported · 3,000 planned enrolment

Countries listed: 1
Registry update: January 14, 2025

Verify in the registry →

TerminatedNCT05266495

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Phase not reported · 3 planned enrolment

Countries listed: 1
Registry update: January 13, 2025

Verify in the registry →

TerminatedNCT05112835

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Phase not reported · 302 planned enrolment

Countries listed: 1
Registry update: October 29, 2024

Verify in the registry →

CompletedNCT04597632

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

PHASE3 · 248 planned enrolment

Countries listed: 16
Registry update: October 9, 2024

Verify in the registry →

CompletedNCT04662944

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Phase not reported · 494 planned enrolment

Countries listed: 5
Registry update: June 18, 2024

Verify in the registry →

CompletedNCT05710471

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

PHASE4 · 30 planned enrolment

Countries listed: 1
Registry update: May 8, 2024

Verify in the registry →

TerminatedNCT03710564

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

PHASE3 · 535 planned enrolment

Countries listed: 2
Registry update: January 30, 2023

Verify in the registry →

CompletedNCT05111743

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Phase not reported · 9,261 planned enrolment

Countries listed: 1
Registry update: December 21, 2021

Verify in the registry →

CompletedNCT05082415

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Phase not reported · 9,456 planned enrolment

Countries listed: 1
Registry update: October 27, 2021

Verify in the registry →

CompletedNCT05037396

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Phase not reported · 9,457 planned enrolment

Countries listed: 1
Registry update: October 12, 2021

Verify in the registry →

WithdrawnNCT04697953

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

PHASE3 · 0 planned enrolment

Countries listed: 0
Registry update: September 23, 2021

Verify in the registry →